Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $188.19 USD
Change Today +4.43 / 2.41%
Volume 1.1M
PRGO On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
Frankfurt
As of 4:15 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Treasury Building

Lower Grand Canal Street

Dublin, 2

Ireland

Phone: 353 1 709 4000

Fax:

Perrigo Company plc, through its subsidiaries, operates as an over-the-counter (OTC) consumer goods and specialty pharmaceutical company worldwide. The company operates as a manufacturer of OTC healthcare products and supplier of infant formulas for the store brand market. The company also provides generic extended topical prescription products, and receives royalties from the sale of the multiple sclerosis drug, Tysabri. The company provides ‘Quality Affordable Healthcare Products’ across various product categories and geographies, primarily in North America, Europe, and Australia, as well as in other markets, including Israel and China. Segments The company’s segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other. CHC segment This segment is focused primarily on the sale of OTC store brand products, including cough, cold, and allergy products; analgesics; gastrointestinal products; smoking cessation products; infant formula and foods; vitamins, supplements; animal health products; and diagnostic products. The company operates in the U.S., the U.K., and Mexico, as well as in Australia. The company offers OTC store brands. Store brand products must meet the same U.S. Food and Drug Administration (FDA) requirements as national brands. This segment also develops, manufactures, and distributes certain branded products when the strategy is synergistic with its store brand business. Branded products include the Good Sense, Sergeant's, Sentry, Herron, Bright Beginnings, and PetArmor brands. In 2015, the company acquired Gelcaps Exportadora de Mexico, S.A. de C.V., the Mexican operations of Durham, North Carolina-based Patheon Inc. This segment markets approximately 4,900 store brand and other products, with approximately 17,800 stock-keeping units (SKUs). The company launched various new CHC products in 2015, including the generic versions of Ensure, Ensure Plus, and Frontline Plus. The company, on its own or in conjunction with partners, received final approval from global health authorities for 156 new products within this segment in 2015. As of June 27, 2015, the company had 123 new product applications pending approval. Customers The company’s customers include major global, national, and regional retail drug, supermarket, and mass merchandise chains, such as Walmart, CVS, Walgreens, Kroger, Target, Dollar General, Rite Aid, Sam’s Club, Costco, Petco, Petsmart, Boots (the U.K.), Tesco (the U.K.), ASDA (the U.K.), Woolworth (Australia), and Coles (Australia), as well as major wholesalers, including McKesson, Cardinal Health (Cardinal Health, Inc.), and AmerisourceBergen. Competition The company’s primary competitors include manufacturers, such as LNK International, Inc.; PL Developments; and Dr. Reddy's Labs, as well as brand-name pharmaceutical and consumer product companies, such as Johnson & Johnson, Pfizer, Bayer AG, Eli Lilly, Nestle S.A. (Gerber), Abbott Nutrition, and Mead Johnson Nutrition Co. BCH segment This segment develops, manufactures, markets, and distributes some of Europe's OTC brands in the natural health and VMS (vitamins, minerals and supplements), cough, cold and allergy, personal care and derma-therapeutics, lifestyle, and anti-parasite categories. In addition, this segment leverages its regulatory, sales, and distribution infrastructure to in-license and sell non-owned brands and generic pharmaceutical products. This segment distributes these products through a network of pharmacies in 36 countries, primarily in Europe. While this segment sells products from approximately 300 brands both on its own and through third parties, it focuses its resources on its ‘Top 20 brands’, which are selected on the basis of their growth potential in the OTC market. Additional resources are allocated to these brands to build positions in the major categories in the OTC market, such as analgesics, cough, cold and allergy, and VMS, while maintaining leadership in smaller branded categories, such as head lice and wart treatments. This segment markets approximately 5,200

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $188.19 USD +4.43

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $79.00 USD +2.62
Hospira Inc $89.92 USD +0.08
Mead Johnson Nutrition Co $78.37 USD +0.19
Mylan NV $51.49 USD +0.36
Sun Pharmaceutical Industries Ltd 902.00 INR +29.10
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 100.0x
Price/Sales 5.8x
Price/Book 2.5x
Price/Cash Flow 210.0x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.